BioCentury
ARTICLE | Company News

Takeda divests stake in Chinese JV

May 23, 2018 10:34 PM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) spokesperson Vince Docherty told BioCentury on Wednesday that the pharma's divestment of critical care and API manufacturing JV Guangdong Techpool Bio-Pharma Co. Ltd. (Guangzhou, China) does not signal a strategic shift by the pharma away from China and emerging markets.

Takeda, which announced on Monday that it sold its 51% stake in Techpool for $280 million, said the deal is in line with its focus on best-in-class therapies in its core therapeutic areas, which include gastroenterology and oncology...